FLT3-ITD targeted therapy for fit AML patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a targeted therapy for people with a specific genetic change in their AML cells called FLT3-ITD. It aims to see if adding this targeted drug to standard chemotherapy improves outcomes for patients who are otherwise healthy enough to receive intensive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with AML and have a specific genetic change called FLT3-ITD.
- You are healthy enough to receive standard strong chemotherapy (your doctor will check this).
- Your white blood cell count is not too high (if it is, you can be treated first to lower it).
- Your liver and kidney function are adequate based on blood tests.
- You have not had any prior AML treatment (except emergency measures to lower white blood cells) or prior treatment with a FLT3 inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a targeted drug called gilteritinib to a standard two-drug combination (venetoclax and azacitidine) for people with a specific genetic change (FLT3 mutation) in their acute myeloid leukemia (AML). The goal is to see if the three drugs together work better than the two alone, for patients who cannot tolerate strong chemotherapy.
This trial is testing a three-drug combination for people newly diagnosed with a type of AML that has a FLT3 mutation. The goal is to see if this treatment works better than standard care.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a new combination of three drugs (gilteritinib, azacitidine, and venetoclax) for people with acute myeloid leukemia (AML) that no longer responds to azacitidine and venetoclax. The goal is to see if this triple therapy can help achieve remission and improve outcomes.
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
This trial tests a new combination of chemotherapy (FLAI) and a targeted drug (Gilteritinib) for adults with acute myeloid leukemia (AML) that has a specific genetic change called FLT3. It aims to see if the combo works better than standard treatment.
Hear when a new AML (Acute Myeloid Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.